{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:59:53Z","timestamp":1791262793710,"version":"4.1.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,7,1]]},"DOI":"10.1093\/rheumatology\/kel004","type":"journal-article","created":{"date-parts":[[2006,1,18]],"date-time":"2006-01-18T03:13:29Z","timestamp":1137554009000},"page":"842-846","source":"Crossref","is-referenced-by-count":144,"title":["Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids"],"prefix":"10.1093","volume":"45","author":[{"given":"L.","family":"Quartuccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Soardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"De Marchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fabris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ferraccioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,1,17]]},"reference":[{"key":"key\n\t\t\t\t20171012074914_BIB1","doi-asserted-by":"crossref","unstructured":"Dispenzieri A, Gorevic PD. Cryoglobulinemia. Hematol Oncol Clin North Am1999;13:1315\u201349.","DOI":"10.1016\/S0889-8588(05)70129-5"},{"key":"key\n\t\t\t\t20171012074914_BIB2","unstructured":"Ferri C, Greco F, Longobardo G et al. Association between hepatitis C virus and mixed essential cryoglobulinemia. Clin Exp Rheumatol1991;9:621\u20134."},{"key":"key\n\t\t\t\t20171012074914_BIB3","doi-asserted-by":"crossref","unstructured":"De Vita S, De Re V, Gasparotto D et al. Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. Arthritis Rheum2000;43:94\u2013102.","DOI":"10.1002\/1529-0131(200001)43:1<94::AID-ANR12>3.0.CO;2-8"},{"key":"key\n\t\t\t\t20171012074914_BIB4","doi-asserted-by":"crossref","unstructured":"Tarantino A, Campise M, Banfi G et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int1995;47:618\u201323.","DOI":"10.1038\/ki.1995.78"},{"key":"key\n\t\t\t\t20171012074914_BIB5","doi-asserted-by":"crossref","unstructured":"Mazzaro C, Zorat F, Caizzi M et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol2005;42:632\u20138.","DOI":"10.1016\/j.jhep.2004.10.031"},{"key":"key\n\t\t\t\t20171012074914_BIB6","doi-asserted-by":"crossref","unstructured":"Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by chimeric mouse human monoclonal antibody to CD20. Blood1994;83:435\u201345.","DOI":"10.1182\/blood.V83.2.435.bloodjournal832435"},{"key":"key\n\t\t\t\t20171012074914_BIB7","doi-asserted-by":"crossref","unstructured":"Zaja F, De Vita S, Mazzaro C et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood2003;101:3827\u201334.","DOI":"10.1182\/blood-2002-09-2856"},{"key":"key\n\t\t\t\t20171012074914_BIB8","doi-asserted-by":"crossref","unstructured":"Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon \u03b1 with an anti-CD20. Blood2003;101:3818\u201326.","DOI":"10.1182\/blood-2002-10-3162"},{"key":"key\n\t\t\t\t20171012074914_BIB9","doi-asserted-by":"crossref","unstructured":"Fra GP, Avanzi GC, Bartoli E. Remission of refractory lupus nephritis with a protocol including rituximab. Lupus2003;12:783\u20137.","DOI":"10.1191\/0961203303lu453cr"},{"key":"key\n\t\t\t\t20171012074914_BIB10","doi-asserted-by":"crossref","unstructured":"Ruggenenti P, Chiurchiu C, Brusegan V et al. Rituximab in idiopathic membranous nephropathy: a one-year prospective. J Am Soc Nephrol2003;14:1851\u20137.","DOI":"10.1097\/01.ASN.0000071511.35221.B3"},{"key":"key\n\t\t\t\t20171012074914_BIB11","doi-asserted-by":"crossref","unstructured":"Roccatello D, Baldovino S, Rossi D et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinemic glomerulonephritis. Nephrol Dial Transplant2004;19:3054\u201361.","DOI":"10.1093\/ndt\/gfh469"},{"key":"key\n\t\t\t\t20171012074914_BIB12","doi-asserted-by":"crossref","unstructured":"Ghijsels E, Lerut E, Vanrenterghem Y, Kuypers D. Anti-CD20 monoclonal antibody (Rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am J Kidney Dis2004;43:E34\u20138.","DOI":"10.1053\/j.ajkd.2003.12.057"},{"key":"key\n\t\t\t\t20171012074914_BIB13","doi-asserted-by":"crossref","unstructured":"Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis2002;61:922\u20134.","DOI":"10.1136\/ard.61.10.922"},{"key":"key\n\t\t\t\t20171012074914_BIB14","doi-asserted-by":"crossref","unstructured":"Gottenberg JE, Guillevin L, Lambotte O et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis2005;64:913\u201320.","DOI":"10.1136\/ard.2004.029694"},{"key":"key\n\t\t\t\t20171012074914_BIB15","doi-asserted-by":"crossref","unstructured":"Anolik JH, Campbell D, Felgar RE et al. The relationship of Fc\u03b3RIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum2003;48:455\u20139.","DOI":"10.1002\/art.10764"},{"key":"key\n\t\t\t\t20171012074914_BIB16","doi-asserted-by":"crossref","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31\u201341.","DOI":"10.1159\/000180580"},{"key":"key\n\t\t\t\t20171012074914_BIB17","doi-asserted-by":"crossref","unstructured":"Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab. Arthritis Rheum2004;50:2580\u20139.","DOI":"10.1002\/art.20430"},{"key":"key\n\t\t\t\t20171012074914_BIB18","doi-asserted-by":"crossref","unstructured":"Hainsworth JD. First-line maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. Semin Oncol2003;30(Suppl. 2):9\u201315.","DOI":"10.1053\/sonc.2003.50023"},{"key":"key\n\t\t\t\t20171012074914_BIB19","doi-asserted-by":"crossref","unstructured":"Weide R, Heymanns J, Pandorf A, Koppler H. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus2003;12:779\u201382.","DOI":"10.1191\/0961203303lu449cr"},{"key":"key\n\t\t\t\t20171012074914_BIB20","doi-asserted-by":"crossref","unstructured":"Chan OTM, Madaio MP, Shlomchik MJ. B cells are required for lupus nephritis in the polygenic, Fas-Intact MRL model of systemic autoimmunity. J Immunol1999;163:3592\u20136.","DOI":"10.4049\/jimmunol.163.7.3592"},{"key":"key\n\t\t\t\t20171012074914_BIB21","unstructured":"Cohen CD, Calvaresi N, Armelloni S et al. CD20-positive infiltrates in human membranous glomerulonephritis. J Nephrol2005;18:328\u201333."}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/45\/7\/842\/14117964\/kel004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T06:18:59Z","timestamp":1683353939000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/rheumatology\/article\/45\/7\/842\/1788587\/Rituximab-treatment-for-glomerulonephritis-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,17]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2006,1,17]]},"published-print":{"date-parts":[[2006,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kel004","relation":{},"ISSN":["1462-0332","1462-0324"],"issn-type":[{"value":"1462-0332","type":"electronic"},{"value":"1462-0324","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,7]]},"published":{"date-parts":[[2006,1,17]]}}}